Vast Therapeutics receives qualified infectious disease product status for BIOC11

Vast Therapeutics

8 October 2019 -  Vast Therapeutics today announced that another of its drug candidates, BIOC11, has been designated as a qualified infectious disease product by the U.S. FDA. 

Vast is a preclinical-stage pharmaceutical company focused on treating respiratory infections through the power of nitric oxide  in a synthetically derived powder-based form. 

The QIDP designation, granted for treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis, will make BIOC11 eligible to benefit from certain incentives for the development of new antibiotics provided under the Generating Antibiotic Incentives Now Act.

Read Vast Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Priority review